Eiger BioPharmaceuticals (STU:72C) Cash Flow for Dividends: €0.00 Mil (TTM As of Dec. 2023)


STU:72C Eiger BioPharmaceuticals Inc STU:72C
10 GF Score
Price €6.18
View Full Analysis

What is Eiger BioPharmaceuticals Cash Flow for Dividends?

Eiger BioPharmaceuticals STU:72C 10 Cash Flow for Dividends is €0.00 Mil as of Dec. 2023. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Eiger BioPharmaceuticals's cash flow for dividends for the six months ended in Dec. 2023 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Eiger BioPharmaceuticals Cash Flow for Dividends Related Terms

Eiger BioPharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Eiger BioPharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eiger BioPharmaceuticals Cash Flow for Dividends Chart

Eiger BioPharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Eiger BioPharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:72C
10GF Score
Eiger BioPharmaceuticals Inc STU:72C
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eiger BioPharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.00 Mil mean?
Eiger BioPharmaceuticals (STU:72C) has a Cash Flow for Dividends of €0.00 Mil as of Dec. 2023. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Eiger BioPharmaceuticals and its competitors.
Is Eiger BioPharmaceuticals' Cash Flow for Dividends too high?
Eiger BioPharmaceuticals' current Cash Flow for Dividends is €0.00 Mil. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' Cash Flow for Dividends compare to EDSA and SIGY?
Eiger BioPharmaceuticals' Cash Flow for Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Eiger BioPharmaceuticals and its competitors. Eiger BioPharmaceuticals's current Cash Flow for Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current Cash Flow for Dividends of €0.00 Mil. The current Cash Flow for Dividends is €0.00 Mil. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current Cash Flow for Dividends is €0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score

Get the complete analysis for STU:72C

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18
Price